Is Cardioprotection Dead?
Is Cardioprotection Dead?
复制标题
DOI：
10.1161/circulationaha.116.027039
复制
发表时间：
2017-07-04
期刊：
影响因子：
37.8
通讯作者：
Marbán E
中科院分区：
文献类型：
--
作者：
Lefer DJ;Marbán E
40多年来，急性心肌梗死治疗的圣杯一直是减轻致命性损伤。尽管心脏病学研究界进行了数十年的研究和有希望的初步结果，但唯一有效的治疗方法是闭塞冠状动脉的早期再灌注。显着的失败记录让我们和其他人怀疑心脏保护是否已经消失。翻译之路，就像攀登珠峰峰一样，肯定是尸横遍野。然而，我们强调了一个提供一线希望的治疗原则：细胞后处理。再灌注后给予心肌球来源的细胞限制了急性测量的梗死面积，同时提供了长期的结构和功能益处。认识到细胞疗法可能是心脏保护的，而不仅仅是再生的，在我们完全放弃追求之前，值得进一步探索。
For >4 decades, the holy grail in the treatment of acute myocardial infarction has been the mitigation of lethal injury. Despite promising initial results and decades of investigation by the cardiology research community, the only treatment with proven efficacy is early reperfusion of the occluded coronary artery. The remarkable record of failure has led us and others to wonder if cardioprotection is dead. The path to translation, like the ascent to Everest, is certainly littered with corpses. We do, however, highlight a therapeutic principle that provides a glimmer of hope: cellular postconditioning. Administration of cardiosphere-derived cells after reperfusion limits infarct size measured acutely, while providing long-term structural and functional benefits. The recognition that cell therapy may be cardioprotective, and not just regenerative, merits further exploration before we abandon the pursuit entirely.